Similar Items: Advances in pharmacotherapy for vascular cognitive impairment and vascular dementia: An update of 2025
- Vascular cognitive impairment and dementia drug‐development pipeline 2025
- Druggable genome‐wide Mendelian randomization analysis identifies potential treatment targets in vascular dementia
- Testing Van Gool’s Hypothesis: A Method to Predict Side Effects of Cholinesterase Inhibitors in Patients with Cellular Degenerative and Vascular Dementia
- Use of Wearable Technology for Measuring and Characterizing Sedentary Behavior in People With Mild Cognitive Impairment and Dementia: Systematic Review
- Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment
- Outcome Measures for Dementia in the Advanced Stage and at the End of Life